NICHOLAS BANKER: Open Payments
NPI 1770060071 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,983 in 122 payments from 16 companies in 2025. Trend: 2023 $1,201 · 2024 $1,405 · 2025 $1,983
Food & beverage: $1,983
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $361 |
| Neurocrine BioSciences, Inc. | 10 | $251 |
| Alkermes, Inc. | 10 | $231 |
| Tris Pharma Inc | 20 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $159 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| E.R. Squibb & Sons, L.L.C. | 2 | $59 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Vanda Pharmaceuticals Inc. | 1 | $37 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, LYBALVI, Dyanavel XR, TRINTELLIX, REXULTI, COBENFY.
Industry payments across NY — which companies pay providers there.
